NCT00258154已完成3 期
Safety and Immunogenicity of Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 403
- 主要终点
- Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg, Predose 1
研究概览
简要总结
The study is being conducted to demonstrate that the vaccine to prevent gastroenteritis due to rotavirus may be administered concomitantly with INFANRIX(tm)hexa without impairing the safety and immunogenicity of either vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 6 Weeks 至 12 Weeks（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy infant per investigator, 6 through 12 weeks of age
排除标准
- •History of congenital abdominal disorders, intussusception, or abdominal surgery
- •Known or suspected impairment of immunological function
- •Known hypersensitivity to any component of the rotavirus vaccine
- •Prior administration of any rotavirus vaccine
- •Known hypersensitivity or contraindication to any component of INFANRIX(tm) hexa
- •Any infant born from a known HBsAg-positive mother
- •Prior administration of any oral polio vaccine
- •Receipt of one or more doses of inactivated poliovirus vaccine, diptheria, tetanus and acellular pertussis vaccine, diptheria, tetanus and pertussis vaccine, Haemophilus influenzae type b vaccine, or any hepatitis B vaccine prior to the first vaccination, or receipt of any vaccines with these antigens at any time during the course of the study
- •Fever, with a rectal temperature greater than or equal to 38.1 degree C (greater than or equal to 100.5 degree F) at the time of immunization
- •History of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to thrive
- •Clinical evidence of active gastrointestinal illness
- •Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 2 weeks prior to vaccination
- •Infants residing in a household with an immunocompromised person
- •Prior receipt of a blood transfusion or blood products
- •Participation in another clinical study within 42 days before the beginning or anytime during the duration of the current clinical study
- •Any infant who cannot be adequately followed for safety by a contact visit
- •History of seizure disorders or prior history followed for safety by a contact visit
- •Any condition that, in the opinion of the investigator, may interfere with the evaluation of the study objectives
结局指标
主要结局
Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg, Predose 1
时间窗: Day 1 of a 3-dose regimen
Geometric Mean Titer (GMT)/antibody responses to RotaTeq™ and INFANRIX™ in relation to anti-hepatitis B surface antigen HBsAg at start of a 3-dose regimen
Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg , at 42 Days After a 3-dose Regimen
时间窗: 42 days after 3-dose regimen
GMT/antibody responses to RotaTeq™ and INFANRIX™ in relation to anti-hepatitis B surface antigen HBsAg at 42 days after 3-dose regimen
Immunogenicity of INFANRIX™ Hexa in Relation to Serum Anti-polyribosylribitol Phosphate PRP, Predose 1
时间窗: Day 1 of 3-dose regimen
GMT/antibody responses to RotaTeq™ and INFANRIX™ hexa in relation to serum anti-polyribosylribitol phosphate PRP at start of 3-dose regimen
Immunogenicity of INFANRIX™ Hexa in Relation to Serum Anti-polyribosylribitol Phosphate PRP at 42 Days After a 3-dose Regimen
时间窗: 42 days after a 3-dose regimen
GMT/antibody responses to RotaTeq™ and INFANRIX™ hexa in relation to serum anti-polyribosylribitol phosphate PRP at 42 days after a 3-dose regimen
次要结局
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 1 When Administered Concomitantly With RotaTeq™, Predose 1(Predose (Day 1 of a 3-dose regimen))
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis FHA When Administered Concomitantly With RotaTeq™, Predose 1(Predose (Day 1 of a 3-dose regimen))
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 3 When Administered Concomitantly With RotaTeq™, Predose 1(Predose (Day 1 of a 3-dose regimen))
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 3 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Serum Neutralizing Antibody (SNA) Response to Serotype G1 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 1 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 2 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen(42 days after in a 3-dose regimen)
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Diphtheria Toxoid When Administered Concomitantly With RotaTeq™, Predose 1(Predose (Day 1 of a 3-dose regimen))
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Diphtheria Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis FHA When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Pertactin When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 2 When Administered Concomitantly With RotaTeq™, Predose 1(Pre-dose (Day 1 of a 3-dose regimen))
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Tetanus Toxoid When Administered Concomitantly With RotaTeq™, Predose 1(Predose (Day 1 of a 3-dose regimen))
- Serum Neutralizing Antibody (SNA) Response to Serotype G2 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Serum Neutralizing Antibody (SNA) Response to Serotype P1A in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1(Predose (Day 1 of a 3-dose regimen))
- Serum Neutralizing Antibody (SNA) Response to Serotype P1A in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Tetanus Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Pertactin When Administered Concomitantly With RotaTeq™, Predose 1(Predose (Day 1 of a 3-dose regimen))
- Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Toxoid When Administered Concomitantly With RotaTeq™, Predose 1(Predose (Day 1 of a 3-dose regimen))
- Serum Neutralizing Antibody (SNA) Response to Serotype G1 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, Predose 1(Predose (Day 1 of a 3-dose regimen))
- Serum Neutralizing Antibody (SNA) Response to Serotype G3 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1(Predose (Day 1 of a 3-dose regimen))
- Serum Neutralizing Antibody (SNA) Response to Serotype G3 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Serum Neutralizing Antibody (SNA) Response to Serotype G2 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, Predose 1(Predose (Day 1 of a 3-dose regimen))
- Serum Neutralizing Antibody (SNA) Response to Serum Anti-rotavirus IgA in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1(Predose (Day 1 of a 3-dose regimen))
- Serum Neutralizing Antibody (SNA) Response to Serotype G4 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1(Predose (Day 1 of a 3-dose regimen))
- Serum Neutralizing Antibody (SNA) Response to Serotype G4 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
- Serum Neutralizing Antibody (SNA) Response to Serum Anti-rotavirus IgA in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen(42 days after a 3-dose regimen)
研究者
相似试验
已完成
3 期
Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)Rotavirus InfectionsGastroenteritisNCT00130832Merck Sharp & Dohme LLC735
已完成
4 期
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) VaccinesTyphoid FeverVaccine-Preventable DiseasesCholeraNCT06104345Helsinki University Central Hospital65
撤回
不适用
Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe GastroenteritisInfections, RotavirusNCT01978223GlaxoSmithKline
Unknown
4 期
The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR VaccineRotavirusNCT02153866Sichuan Center for Disease Control and Prevention2,800
已完成
1 期
Norovirus Bivalent-Vaccine Efficacy StudyPrevention From Norovirus InfectionNCT01609257Takeda132